NCT03194646 2025-07-28
ASTEROID 6
Bayer
Phase 3 Terminated
Clinical Trials
26 trialsNCT03118037 2024-12-16
SAGE
Gynesonics
Terminated
NCT03240523 2024-10-18
ASTEROID 5
Bayer
Phase 3 Terminated
NCT05026502 2023-08-14
REACH
AbbVie
Terminated
NCT03400943 2023-05-03
Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 3)
Bayer
Phase 3 Terminated
NCT03476928 2022-07-08
ASTEROID 8
Bayer
Phase 3 Terminated
NCT03400956 2022-06-30
Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 4)
Bayer
Phase 3 Terminated
NCT03342859 2021-01-06
Mode of Action Study of Vilaprisan and Ulipristal Acetate in Patients With Uterine Fibroids for Whom Surgery is Planned
Bayer
Phase 1 Terminated
NCT03210324 2019-08-07
A Study on the Mifepristone Tablets in the Treatment of Symptomatic Uterine Fibroids With Safety and Efficacy
China Resources Zizhu Pharmaceutical Co., Ltd.
Phase 4 Terminated
NCT02811159 2019-06-27
An Extension Study of 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids
Repros Therapeutics Inc.
Phase 2 Terminated
NCT00730886 2018-08-15
ExAblate Treatment of Uterine Fibroids for Fertility Enhancement
InSightec
Phase NA Terminated
NCT01842789 2017-08-18
TAG
Acessa Health, Inc.
Phase NA Terminated
NCT01504308 2017-04-05
SOFIA
Philips Healthcare
Phase 2/3 Terminated
NCT01675011 2016-03-11
Embozene Microspheres for Uterine Fibroid Embolization (UFE)
Boston Scientific Corporation
Phase NA Terminated
NCT01226290 2015-04-02
FAST-EU
Gynesonics
Phase NA Terminated
NCT01539187 2015-03-17
FAST-L
Gynesonics
Phase NA Terminated
NCT01998854 2015-03-11
Observational Prospective Study on Patients With Symptomatic Uterine Fibroids Treated With VizAblate® Intrauterine-ultrasound Guided RF Ablation
Gynesonics
Terminated
NCT00958893 2014-08-25
An Extension Study Evaluating Safety and Efficacy of Proellex® In Women Who Have Previously Completed ZPU 003 Ext
Repros Therapeutics Inc.
Phase 2 Terminated
NCT00683917 2014-08-21
Pharmacokinetics, Safety and Efficacy Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids
Repros Therapeutics Inc.
Phase 2 Terminated
NCT00737282 2014-08-21
Multicenter Study Evaluating the Safety of Proellex® in Premenopausal Women With Uterine Fibroids
Repros Therapeutics Inc.
Phase 3 Terminated
NCT00785356 2014-08-21
Safety and Efficacy of Proellex in Pre-Menopausal Anemic Women With Symptomatic Uterine Fibroids
Repros Therapeutics Inc.
Phase 3 Terminated
NCT00853567 2014-08-21
Evaluating the Safety and Efficacy of Proellex® in Premenopausal Women With Symptomatic Uterine Fibroids
Repros Therapeutics Inc.
Phase 3 Terminated
NCT01069120 2014-08-21
Safety of 25 and 50 mg Proellex® in the Treatment of Women With Symptomatic Uterine Fibroids
Repros Therapeutics Inc.
Phase 3 Terminated
NCT00496080 2012-09-10
DUAO
Ethicon, Inc.
Phase NA Terminated
NCT00496067 2011-03-09
Uterine Artery Occlusion for Fibroid Related Bleeding
Ethicon, Inc.
Phase NA Terminated
NCT01140555 2011-02-17
A Pilot Study to Determine Optimal Procedure Steps to Obtain and Maintain Uterine Artery Occlusion With the D-UAO Device
Ethicon, Inc.
Phase NA Terminated